The tumor microenvironment (TME) in intrahepatic cholangiocarcinoma (iCCA) plays a pivotal role in tumor progression, immune evasion, and therapeutic resistance. iCCA is characterized by a highly complex and heterogeneous TME, comprising cancer cells, immune cells, stromal cells, extracellular matrix components, and signaling molecules.
The tumor microenvironment (TME) in intrahepatic cholangiocarcinoma (iCCA) plays a pivotal role in tumor progression, immune evasion, and therapeutic resistance. iCCA is characterized by a highly complex and heterogeneous TME, comprising cancer cells, immune cells, stromal cells, extracellular matrix components, and signaling molecules. This intricate environment influences tumor growth, metastasis, and response to treatments.
Key players in the TME include tumor-associated macrophages, particularly CD163hi M2-like macrophages, which promote immune suppression and tumor progression by impairing CD8+ T cell-mediated antitumor responses. Cancer-associated fibroblasts (CAFs) contribute to the formation of a fibrotic barrier, preventing immune cell infiltration and creating an immunosuppressive milieu. Granulocytes and other myeloid cells further exacerbate immune suppression.
The TME in iCCA can be classified into distinct spatial subtypes, such as "immune hot," "immune suppressive," and "immune desert," which correlate with prognosis and treatment response. For example, immune hot TMEs, enriched in antitumor immune cells, are more responsive to immunotherapy, while immune desert TMEs, lacking immune cells, are associated with poor outcomes.
By influencing immune evasion mechanisms and modulating therapy resistance, the TME is a critical determinant of iCCA progression. Targeting the TME through combination therapies, such as immunotherapy and antifibrotic agents, holds promise for improving patient outcomes.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.